CPT-Pharmacometrics & Systems Pharmacology

Article	Citations
Issue Information	46
Issue Information	42
Issue Information	40
Issue Information	37
Pharmacokinetics of Intrapartum Benzylpenicillin: Insights Into Candidate Regimens to Prevent Early Onset Neonatal Group B Streptococcus Disease	35
Designing phase I oncology dose escalation using dose–exposure–toxicity models as a complementary approach to model‐based dose–toxicity models	33
Genotype, Ethnicity, and Drug–Drug Interaction Modeling as Means of Verifying Transporter Biomarker PBPK Model: The Coproporphyrin‐I Story	32
Regulatory utility of physiologically based pharmacokinetic modeling for assessing food impact in bioequivalence studies: A workshop summary report	32
Development of a physiologically based pharmacokinetic model of fostemsavir and its pivotal application to support dosing in pregnancy	31
Association between SARS‐CoV‐2 viral kinetics and clinical score evolution in hospitalized patients	28
Concentration‐QTc and cardiac safety analysis of single and multiple zavegepant nasal spray doses in healthy participants to support approval	28
Evaluation of postprandial total triglycerides within the TIGG model for characterizing postprandial response of glucose, insulin, and GLP‐1	27
Issue Information	27
Quantitative Systems Pharmacology Model to Predict Target Occupancy by Bruton Tyrosine Kinase Inhibitors in Patients With B‐Cell Malignancies	23
Enhance Multistate Models With Clinically Meaningful Graphs	23
Translational Physiologically Based Pharmacokinetic Modeling to Predict Human Pulmonary Kinetics After Lung Delivery	23
Correction to Network module‐based drug repositioning for pulmonary arterial hypertension	22
Physiologically‐based pharmacokinetic modeling of pantoprazole to evaluate the role of CYP2C19 genetic variation and obesity in the pediatric population	22
A case‐study of model‐informed drug development of a novel PCSK9 anti sense oligonucleotide. Part 1: First time in man to phase II	21
Building Hybrid Pharmacometric‐Machine Learning Models in Oncology Drug Development: Current State and Recommendations	21
Prediction of a CLDN18.2 Targeted Antibody Drug Conjugate Pharmacokinetics in Cancer Patients Using PBPK Modeling and Simulation	20
Clinical pharmacokinetics of leriglitazone and a translational approach using PBPK modeling to guide the selection of the starting dose in children	20
Physiologically‐based pharmacokinetic model of sparsentan to evaluate drug–drug interaction potential	19
A Quantitative Systems Pharmacology (QSP) Model of Acute Hepatitis B Virus Infection: Mechanistic Insights and Foundations for Future Extensions	19
Exposure–response modeling for nausea incidence for cotadutide using a Markov modeling approach	19

Mathematical model of the relationship between pH holding time and erosive esophagitis healing rates	19
Evaluation of covariate effects in item response theory models	19
Tutorial on Causal Mediation Analysis for Pharmacometricians	19
A systematic efficacy analysis of tuberculosis treatment with BPaL‐containing regimens using a multiscale modeling approach	18
Pharmacometric and statistical considerations for dose optimization	18
Adaptive Dosing Trial Simulation Framework to Inform Dose Optimization: Case Study Using Longitudinal PKPD Models With PF	18
Interspecies and in vitro‐in vivo scaling for quantitative modeling of whole‐body drug pharmacokinetics in patients: Application to the anticancer drug oxaliplatin	17
The Role of Estradiol in Oxidative Stress in Health and Cystathionine ß‐Synthase Deficiency: A Mechanistic Model	17
Regulatory utility of physiologically‐based pharmacokinetic modeling to support alternative bioequivalence approaches and risk assessment: A workshop summary report	17
Characterization of mavacamten pharmacokinetics in patients with hypertrophic cardiomyopathy to inform dose titration	17
Impact of Mechanistic Modeling and Simulation Methodologies on Product‐Specific Guidance Development for Non‐Orally Administered Drug Products	17
Tutorial on model selection and validation of model input into precision dosing software for model‐informed precision dosing	16
Using PBPK modeling to supplement clinical data and support the safe and effective use of dolutegravir in pregnant and lactating women	16
Physiologically‐based pharmacokinetic pharmacodynamic parent‐metabolite model of edoxaban to predict drug–drug‐disease interactions: M4 contribution	16
Model‐based simulation to support the approval of isatuximab alone or with dexamethasone for the treatment of relapsed/refractory multiple myeloma in Japanese patients	16
Issue Information	16
Application of physiologically‐based pharmacokinetic model approach to predict pharmacokinetics and drug–drug interaction of rivaroxaban: A case study of rivaroxaban and carbamazepine	16
Predictive AI in Clinical Pharmacology: A Call to Action to Develop Robust Benchmarking Practices	16
Using Virtual Patients to Evaluate Dosing Strategies for Bispecifics With a Bell‐Shaped Efficacy Curve	16
Talazoparib Formulation Bridging in Cancer Patients—Challenges and the Critical Role of Model‐Informed Drug Development in Approval Despite Failed Bioequivalence	16
Pharmacokinetic/pharmacodynamic analysis of geographic atrophy lesion area in patients receiving pegcetacoplan treatment or sham	16
Quantitative systems toxicology modeling in pharmaceutical research and development: An industry‐wide survey and selected case study examples	15
Shap‐Cov: An Explainable Machine Learning Based Workflow for Rapid Covariate Identification in Population Modeling	15
The population pharmacokinetics of dolutegravir co‐administered with rifampicin in Thai people living with HIV: Assessment of alternative dosing regimens	15
	15
Retrieval Augmented Generation ( RAG ) for Evaluating Regulatory Compliance of Drug Information and Clinical Trial Protocols	14
Development and Verification of a Physiologically Based Pharmacokinetic Model of Furmonertinib and Its Main Metabolite for Drug–Drug Interaction Predictions	14
Population Pharmacokinetics and Transfer of Gabapentin When Used as a Pain Adjunct for Cesarean Deliveries	14
Issue Information	14
A mechanistic PK/PD model of AZD0171 (anti‐LIF) to support Phase II dose selection	14
Mechanistic pharmacokinetic–pharmacodynamic modeling and simulations of naloxone auto‐injector 10 mg reversal of opioid‐induced respiratory depression	14
The interaction of core modules as a basis for elucidating network behavior determining Parkinson's disease pathogenesis	14
	14
Physiologically based mechanistic insight into differential risk of valproate hepatotoxicity between children and adults: A focus on ontogeny impact	13
Variable or variate? A conundrum in pharmacometrics exposure–response models	13
Longitudinal and time‐to‐event modeling for prognostic implications of radical surgery in retroperitoneal sarcoma	13
A physiologically‐based pharmacokinetic modeling approach for dosing amiodarone in children on ECMO	13
Population pharmacokinetic and pharmacodynamic model of evogliptin: Severe uremia increases the bioavailability of evogliptin	13
Physiologically based pharmacokinetic modeling of drug–drug interactions between ritonavir‐boosted atazanavir and rifampicin in pregnancy	13
	13
CYTOCON: The manually curated database of human in vivo cell and molecule concentrations	13
	12
Quantitative Systems Toxicology Modeling of Acetaminophen Pharmacokinetics and Hepatic Biomarkers After Overdoses of Extended‐Release and Immediate‐Release Formulations in Adults With Chronic Alcohol	12
Regulatory utility of mechanistic modeling to support alternative bioequivalence approaches: A workshop overview	12
Tutorial for Modeling Delays in Biological Systems in the NONMEM Software	12
Precision Medicine in Oncology: Imatinib Dosing in the Obese Cancer Population Using Virtual Clinical Trials	12
Multivariate modeling of magnetic resonance biomarkers and clinical outcome measures for Duchenne muscular dystrophy clinical trials	12
Issue Information	12
	12
Issue Information	12

Type 1 diabetes prevention clinical trial simulator: Case reports of model‐informed drug development tool	12
Modeling of Disease Progression of Type 2 Diabetes Using Real‐World Data: Quantifying Competing Risks of Morbidity and Mortality	12
Flexible and efficient Bayesian pharmacometrics modeling using Stan and Torsten, Part I	12
Midazolam Dosing During CRRT: A Combined Ex Vivo and Physiologically‐Based Pharmacokinetic Approach	12
	12
Mid‐dosing interval concentration is important for polymyxin B exposure and acute kidney injury in critically ill patients	12
Issue Information	12
Predicting Residual 21‐Hydroxylase Enzymatic Activity in Pediatric and Adult Congenital Adrenal Hyperplasia Patients: Towards Individualized Therapy	12
SCOUT: An Exploratory Approach to Scouting Dose‐Relevant Covariates	12
Activity and perspective on quantitative modeling and simulation in Japan: Update from the Pharmaceuticals and Medical Devices Agency	12
Population PK – PD Modeling of Danicopan Add‐On Therapy in Participants With Paroxysmal Nocturnal	12
Development of and insights from systems pharmacology models of antibody‐drug conjugates	11
Evaluation of the Drug–Drug Interaction Potential of the GlyT1 Inhibitor Iclepertin (BI 425809): A Physiologically Based Pharmacokinetic (PBPK) Modeling Approach	11
Population pharmacokinetic modeling of zavegepant, a calcitonin gene‐related peptide receptor antagonist, in healthy adults and patients with migraine	11
Population PK modeling of certolizumab pegol in pregnant women with chronic inflammatory diseases	11
Medicines in pregnancy: A clinical pharmacology extrapolation framework to address knowledge gaps	11
Tumor growth inhibition modeling in patients with second line biliary tract cancer and first line non‐small cell lung cancer based on bintrafusp alfa trials	11
Evaluation of the potential impact on pharmacokinetics of various cytochrome P450 substrates of increasing IL‐6 levels following administration of the T‐cell bispecific engager g	11
Model‐based meta‐analysis using latent variable modeling to set benchmarks for new treatments of systemic lupus erythematosus	11
	11
Physiologically‐based pharmacokinetic modeling for investigating the effect of simeprevir on concomitant drugs and an endogenous biomarker of OATP1B	11
Quantitative systems pharmacology model of the amyloid pathway in Alzheimer's disease: Insights into the therapeutic mechanisms of clinical candidates	11
The influence of flip‐flop in population pharmacokinetic analyses	11
Population pharmacokinetics modeling and exposure‐response analyses of cemiplimab in patients with recurrent or metastatic cervical cancer	11
Population Pharmacokinetic and Exposure‐Response Analyses of Ibrutinib Combined With Bendamustine and Rituximab in Patients With Mantle Cell Lymphoma	10
PBPK modeling: What is the role of CYP3A4 expression in the gastrointestinal tract to accurately predict first‐pass metabolism?	10
Item performance of the scale for the assessment and rating of ataxia in rare and ultra‐rare genetic ataxias	10
A literature review of drug transport mechanisms during lactation	10
Issue Information	10
Multi‐model averaging improves the performance of model‐guided infliximab dosing in patients with inflammatory bowel diseases	10
Semimechanistic modeling of copeptin and aldosterone kinetics and dynamics in response to rehydration treatment for diabetic ketoacidosis in children	10
Development of a Predictive Flow Through Cell Dissolution Method for Carbamazepine Modified‐Release Tablets	10
State‐of‐the‐Art on Model‐Informed Drug Development Approaches for Pediatric Rare Diseases	10
Continuous‐Time Markov Population PK/PD Modeling of Longitudinal EASI Categorical Score in Atopic Dermatitis Treated With Rocatinlimab, an Anti‐OX40 Monoclonal Antibody	10
Toward improved predictions of pharmacokinetics of transported drugs in hepatic impairment: Insights from the extended clearance model	10
Low‐dimensional neural ordinary differential equations accounting for inter‐individual variability implemented in Monolix and NONMEM	10
A Pragmatic Approach to Handling Censored Data Below the Lower Limit of Quantification in Pharmacokinetic Modeling	10
Elucidating Contributions of Drug Transporters/Enzyme to Nonlinear Pharmacokinetics of Grazoprevir by PBPK Modeling With a Cluster Gauss–Newton Method	10
Evaluation of the drug–drug interaction potential of brigatinib using a physiologically‐based pharmacokinetic modeling approach	10
Moving From Point‐Based Analysis to Systems‐Based Modeling: Knowledge Integration to Address Antimicrobial Resistance	10
Quantitative systems pharmacology in the age of artificial intelligence	10
Semi‐Mechanistic Population Pharmacokinetic/Pharmacodynamic (PK/PD) Modeling of Dupilumab on Pre‐Bronchodilator Forced Expiratory Volume in 1 Second (FEV1)	10
Population pharmacokinetic modeling of oral brepocitinib in healthy volunteers and patients with immuno‐inflammatory diseases	10
A Model‐Based Approach to Evaluate Anti‐Drug Antibody Impact on Drug Exposure With Biologics: A Case Example With the CD3 T‐Cell Bispecific Cibisatamab	10
Maximum likelihood estimation of renal transporter ontogeny profiles for pediatric PBPK modeling	10
An Interactive Pharmacokinetic‐Pharmacodynamic Framework to Evaluate Bedaquiline Dose Modifications in Adults With Tuberculosis	9
Impact of Event‐Related Treatment Modifications in Exposure‐Response Analyses of Repeated Time‐to‐Event Data	9
Issue Information	9
	9
Postmarketing Assessment of Antibody–Drug Conjugates: Proof‐of‐Concept Using Model‐Based Meta‐Analysis and a Clinical Utility Index Approach	9
Albumin Levels Are Predictive of Cachexia‐Induced Time‐Dependent Clearance of Therapeutic Antibodies: A Physiologically Based Pharmacokinetic Model of Durvalumab	9
Population pharmacokinetics of intraperitoneal irinotecan and SN‐38 in patients with peritoneal metastases from colorectal origin	9
Elucidating nonlinear pharmacokinetics of telmisartan: Integration of target‐mediated drug disposition and OATP1B3‐mediated hepatic uptake in a physiologically based model	9
Causal Directed Acyclic Graphs to Mitigate Confounding Bias in Exposure‐Response Analyses	9
	9
Application of Physiologically‐Based Pharmacokinetic Modeling to Support Drug Labeling: Prediction of CYP3A4 ‐Mediated Pirtobrutinib‐Drug Interaction	9
Development of a cystic fibrosis population model for physiologically based pharmacokinetic models: Is it worth it?	9
Issue Information	9
Machine Learning‐Based Model Selection and Averaging Outperform Single‐Model Approaches for a Priori Vancomycin Precision Dosing	9
Open Systems Pharmacology Community Conference ( OSP ‐ CC ) Proceedings 2025	9
Anti‐ PD ‐(L)1 Antibodies: Insights From QSP ‐Based Meta‐Analysis	9
Within‐chain parallelization—Giving Stan Jet Fuel for population modeling in pharmacometrics	9
Mechanistic modeling projections of antibody persistence after homologous booster regimens of COVID‐19 vaccine Ad26.COV2.S in humans	9
Model‐Based Meta‐Analysis of the Relationship Between Pioglitazone and Histological Outcomes in Metabolic Dysfunction‐Associated Steatohepatitis Patients	9
Physiologically based pharmacokinetic modeling for development and applications of a virtual celiac disease population using felodipine as a model drug	8
Population model‐based analysis of the memory B‐cell response following belimumab therapy in the treatment of systemic lupus erythematosus	8
Predicting the correct dose in children: Role of computational Pediatric Physiological‐based pharmacokinetics modeling tools	8
Population pharmacokinetic analysis for tisotumab vedotin in patients with locally advanced and/or metastatic solid tumors	8
Using mechanistic models to support development of complex generic drug products: European Medicines Agency perspective	8
Issue Information	8
Synthetic Model Combination: A new machine‐learning method for pharmacometric model ensembling	8
Supplementing clinical lactation studies with PBPK modeling to inform drug therapy in lactating mothers: Prediction of primaquine exposure as a case example	8
A Pharmacometric Workflow for Resolving Model Instability in Model Use‐Reuse Settings	8
Assessment and Benchmarking of Model Informed Approaches in Drug Development for Hemoglobinopathies: A Review of Scientific Advices From January 2000 to December 2024	8
Population pharmacokinetic analyses for belzutifan to inform dosing considerations and labeling	8
Isavuconazole and Calcium Channel Blocker for Invasive Fungal Disease Accompanied With Hypertension: Evidence From the FAERS and PBPK/PD Model	8
QPRapp: A Web‐Based Platform for PK/PD Simulations and Early Feasibility Analysis	8
Population pharmacokinetics of amodiaquine and piperaquine in African pregnant women with uncomplicated Plasmodium falciparum infections	8
Development and comparison of model‐integrated evidence approaches for bioequivalence studies with pharmacokinetic end points	8
Population pharmacokinetics and exposure–clinical outcome relationship of remdesivir major metabolite GS‐441524 in patients with moderate and severe COVID‐19	8

Physiologically‐based pharmacokinetic modeling for primary metabolites of CYP3A and P‐glycoprotein inhibitors in drug–drug interactions: Should we assume the free drug hypothesis?	8
Tackling High Dimensionality in QSP : Guiding Model Order Reduction With Index Analysis	7
Development of a Joint Tumor Size–Overall Survival Modeling and Simulation Framework Supporting Oncology Development Decision‐Making	7
	7
A Population Pharmacokinetic Model to Inform Extension of the Eteplirsen Dosing Regimen Across the Broad DMD Population	7
A dynamic model of the intestinal epithelium integrates multiple sources of preclinical data and enables clinical translation of drug‐induced toxicity	7
Deep‐NCA: A deep learning methodology for performing noncompartmental analysis of pharmacokinetic data	7
Pharmacokinetic Model‐Informed Precision Dosing of Natalizumab in Multiple Sclerosis	7
Population pharmacokinetics and exposure–response analyses of polatuzumab vedotin in patients with previously untreated DLBCL from the POLARIX study	7
The Regularized Horseshoe for Covariate Selection Improves Convenience and Predictive Performance in Population PK / PD	7
Population Pharmacokinetic Analysis of Datopotamab Deruxtecan (Dato‐ DXd ), a TROP2 ‐Directed Anti	7
Population Pharmacokinetics and Exposure‐Response of Subcutaneous Atezolizumab in Patients With Non‐Small Cell Lung Cancer	7
Item Response Modeling and Artificial Neural Network for Differentiation of Parkinson's Patients and Subjects Without Evidence of Dopaminergic Deficit	7
Development of a PBPK model to quantitatively understand absorption and disposition mechanism and support future clinical trials for PB‐201	7
A fully automatic tool for development of population pharmacokinetic models	7
Delineating gene–environment effects using virtual twins of patients treated with clozapine	7
Issue Information	7
Using PBPK to Simulate Target Biopredictive Dissolution Profiles for Long‐Acting Injectables ‐ Where to Begin With Critical Bioavailability Attribute	7
Integrating MBMA and QSP to Identify Key Covariates and Predict Treatment Outcomes in Relapsed/Ref	7
Quantitative systems pharmacology model of α‐synuclein pathology in Parkinson's disease‐like mouse for investigation of passive immunotherapy mechanisms	7
Disease–Drug–Drug Interaction of Imatinib in COVID‐19 ARDS: A Pooled Population Pharmacokinetic Analysis	7
Response to “Enhance Multistate Models With Clinically Meaningful Graphs”	7
Population Physiologically‐Based Pharmacokinetic Modeling to Determine Ontogeny: A Quantitative Clinical Pharmacology Example in Pediatric Rare Disease	7
Evaluation and Mitigation of Time‐Dependent Confounding Effects in Conventional Exposure‐Response Analyses for Oncology Drugs	7
Analyzing Pharmacodynamic Count Data That Rapidly Decrease to Zero	7
Issue Information	7
A multi‐model approach to predict efficacious clinical dose for an anti‐TGF‐β antibody (GC2008) in the treatment of osteogenesis imperfecta	7
Population Pharmacokinetics and Exposure‐Response Analysis of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia Patients With NPM1	7
	7
Mechanistic modeling of drug products applied to the skin: A workshop summary report	7
Exposure‐Efficacy Meta‐Model of Nintedanib in Adult Patients With Chronic Fibrosing Interstitial Lung Diseases	7
Stochastic Gates for Covariate Selection in Population Pharmacokinetics Modeling	7
Applying interpretable machine learning workflow to evaluate exposure–response relationships for large‐molecule oncology drugs	7
Combining Aggregate Data and Individual Patient Data in Model‐Based Meta‐Analysis: An Illustrative Case Study of Tofacitinib in Rheumatoid Arthritis Patients	7
From In Vitro Efficacy to Long‐Term HbA1c Response for GLP‐1R/GlucagonR Agonism Using the 4GI‐HbA1c Systems Model	6
Development of the Weight‐Tiered Q3W Regimen of Amivantamab in Combination With Carboplatin‐Pemetrexed in EGFR	6
Issue Information	6
Evaluation of the PK / PD Changes on MASLD ‐Rel	6
A Model‐Based Meta‐Analysis of Pembrolizumab Effects on Patient‐Reported Quality of Life: Advancing Patient‐Centered Oncology Drug Development	6
Corrigendum to: 2022 WCoP Abstracts	6
Population Pharmacokinetic Model of Pegbing in Healthy Subjects and Chronic Hepatitis B Patients	6
In memoriam Lambertus (“Bert”) A. Peletier 29 March 1937–16 December 2023: Furthering quantitative pharmacology through applied mathematics	6
Issue Information	6
Development and application of a PBPK modeling strategy to support antimalarial drug development	6
Informing pregnancy dose via target‐mediated drug disposition modeling and simulations for a recombinant human monoclonal antibody	6
	6
Navigating the landscape of parameter identifiability methods: A workflow recommendation for model development	6
Computational design of clinical trials using a combination of simulation and the genetic algorithm	6
What Is a Digital Twin in QSP , and Are We Doing It Right?	6
Application of longitudinal item response theory models to modeling Parkinson’s disease progression	6
Mixed‐effects models and the drug titration paradox	6
Physiologically‐based pharmacokinetic modeling of immunoglobulin and antibody coadministration in patients with primary human immunodeficiency	6
Growth‐rate model predicts in vivo tumor response from in vitro data	6
Mechanistic modeling of ophthalmic, nasal, injectable, and implant generic drug products: A workshop summary report	6
Biased computation of probability of target attainment for antimicrobial drugs	6
Using Pharmacokinetic and Pharmacodynamic Analysis to Optimize the Dosing Regimens of Fanastomig (EMB‐02) in Patients With Advanced Solid Tumors	6
Population pharmacokinetic analysis of sparsentan in healthy volunteers and patients with focal segmental glomerulosclerosis	6
PBPK Modeling to Predict Clinical Drug–Drug Interaction and Impact of Hepatic Impairment for an ADC With the Payload Auristatin F‐Hydroxypropylamide	6
Pharmacokinetics, Pharmacodynamics, Efficacy and Drug Resistance Selection of Injectable Long‐Acting Lenacapavir Pre‐Exposure Prophylaxis ( PrEP ) Ag	6
Effect of Cumulative Exposure on the Efficacy of Paroxetine: A Population Pharmacokinetic‐Pharmacodynamic and Machine Learning Analyses	6
Skipping a pillar does not make for strong foundations: Pharmacokinetic‐pharmacodynamic reasoning behind the shape of dose–response relationships in oncology	6
Population Pharmacokinetic Modeling and Pediatric Exposure of Dexamethasone Sodium Phosphate Encapsulated in Erythrocytes (eDSP) Administered Monthly for Treatment of Neurological Symptoms of Patients	6
Virtual Clinical Trial Reveals Significant Clinical Potential of Targeting Tumor‐Associated Macrophages and Microglia to Treat Glioblastoma	6
Preclinical side effect prediction through pathway engineering of protein interaction network models	6
Developmental pharmacokinetics of indomethacin in preterm neonates: Severely decreased drug clearance in the first week of life	6
Multistate modeling for survival analysis in critically ill patients treated with meropenem	6
Optimizing the design of a pharmacokinetic trial to evaluate the dosing scheme of a novel tuberculosis drug in children living with or without HIV	6
Impact of Obesity and MASH on Zonal Hepatocellular Statin Exposure: Pharmacodynamic Insights From a Permeability‐Limited Multicompartment Liver Model	6
Unraveling the Link Between Azathioprine and Acute Pancreatitis: Integrating Network Toxicology, Machine Learning, and Mendelian Randomization	6
PBPK perspective on alternative CYP3A4 inducers for rifampin	6
Population pharmacokinetic analysis of etrolizumab in patients with moderately‐to‐severely active ulcerative colitis	6
Hepatic OATP1B zonal distribution: Implications for rifampicin‐mediated drug–drug interactions explored within a PBPK framework	6
Quantitative Systems Pharmacology Modeling Amid the Rise of Agentic AI	6
A Step‐by‐Step Workflow for Performing In Silico Clinical Trials With Nonlinear Mixed Effects Models	6
Full random effects models (FREM): A practical usage guide	5
Informing the risk assessment related to lactation and drug exposure: A physiologically based pharmacokinetic lactation model for pregabalin	5
The Evolving Role of In Vitro–In Vivo Correlation in Model‐Informed Drug Development: A Multi‐Stakeholder Perspective	5
Recommendation of mavacamten posology by model‐based analyses in adults with obstructive hypertrophic cardiomyopathy	5
Population Pharmacokinetics and Exposure‐Response Relationship of Hemoporfin in Pediatric Patients With Port‐Wine Stain	5
Consistent methods for fat‐free mass, creatinine clearance, and glomerular filtration rate to describe renal function from neonates to adults	5
	5
Population pharmacokinetics and exposure‐response analysis of a single dose of sotrovimab in the early treatment of patients with mild to moderate COVID‐19	5
Quantitative modeling of tumor dynamics and development of drug resistance in non‐small cell lung cancer patients treated with erlotinib	5
Increasing impact of quantitative methods and modeling in establishment of bioequivalence and characterization of drug delivery	5
Pharmacometrics enhanced Bayesian borrowing approach to improve clinical trial efficiency: Case of empagliflozin in type 2 diabetes	5
Adult and pediatric physiologically‐based biopharmaceutics modeling to explain lamotrigine immediate release absorption process	5
Disease Modeling and External Model Evaluation Through Clinical Data Sharing Platform for HR+/HER2− Breast Cancer	5
Risk Assessment for Drug‐Induced Hyperbilirubinemia: A Mechanistic Approach	5
Pharmacokinetics and exposure–safety relationship of ciprofol for sedation in mechanically ventilated patients in the intensive care unit	5
Mitigating Trastuzumab‐Doxorubicin Cardiotoxicity With Multiscale Quantitative Systems Toxicology and PBPK‐Toxicodynamic Predictive Modeling Framework	5
Comparative Analysis of Isavuconazole DDIs With Other Azole Antifungal Drugs and PBPK Model‐Inform	5
Exposure–Response Modeling of Monthly Migraine Days for Efficacy of Atogepant in Patients With Episodic or Chronic Migraine	5
Tipifarnib physiologically‐based pharmacokinetic modeling to assess drug–drug interaction, organ impairment, and biopharmaceutics in healthy subjects and cancer patients	5
	5
Joint modeling of monocyte HLA‐DR expression trajectories predicts 28‐day mortality in severe SARS‐CoV‐2 patients	5